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Abstract
Background: The use of extracorporeal shock wave lithotripsy (ESWL) to treat calcium oxalate
dihydrate (COD) renal calculi gives excellent fragmentation results. However, the retention of
post-ESWL fragments within the kidney remains an important health problem. This study examined
the effect of various urinary conditions and crystallization inhibitors on the regrowth of
spontaneously-passed post-ESWL COD calculi fragments.
Methods: Post-ESWL COD calculi fragments were incubated in chambers containing synthetic
urine varying in pH and calcium concentration: pH = 5.5 normocalciuria (3.75 mM), pH = 5.5
hypercalciuria (6.25 mM), pH = 6.5 normocalciuria (3.75 mM) or pH = 6.5 hypercalciuria (6.25 mM).
Fragment growth was evaluated by measuring increases in weight. Fragment growth was
standardized by calculating the relative mass increase.
Results: Calcium oxalate monohydrate (COM) crystals formed on COD renal calculi fragments
under all conditions. Under pH = 5.5 normocalciuria conditions, only COM crystals formed
(growth rate = 0.22 ± 0.04 µg/mg·h). Under pH = 5.5 hypercalciuria and under pH = 6.5
normocalciuria conditions, COM crystals and a small number of new COD crystals formed (growth
rate = 0.32 ± 0.03 µg/mg·h and 0.35 ± 0.05 µg/mg·h, respectively). Under pH = 6.5 hypercalciuria
conditions, large amounts of COD, COM, hydroxyapatite and brushite crystals formed (growth
rate = 3.87 ± 0. 34 µg/mg·h). A study of three crystallization inhibitors demonstrated that phytate
completely inhibited fragment growth (2.27 µM at pH = 5.5 and 4.55 µM at pH = 6.5, both under
hypercalciuria conditions), while 69.0 µM pyrophosphate caused an 87% reduction in mass under
pH = 6.5 hypercalciuria conditions. In contrast, 5.29 mM citrate did not inhibit fragment mass
increase under pH = 6.5 hypercalciuria conditions.
Conclusion: The growth rate of COD calculi fragments under pH = 6.5 hypercalciuria conditions
was approximately ten times that observed under the other three conditions. This observation
suggests COD calculi residual fragments in the kidneys together with hypercalciuria and high
urinary pH values may be a risk factor for stone growth. The study also showed the effectiveness
of specific crystallization inhibitors in slowing calculi fragment growth.
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Background
Calcium oxalate dihydrate renal calculi constitute the
most prevalent and recurrent type of renal lithiasis [1,2].
They are usually associated with hypercalciuria, and on
occasions with urinary pH values above 6.0 [3-7]. The use
of extracorporeal shock wave lithotripsy (ESWL) to treat
these renal calculi commonly gives excellent fragmenta-
tion results due to their fragility [8]. Nevertheless, the
retention of post-ESWL fragments within the kidney is an
important health problem, and a study of calcium stone
patients found only 32% were stone-free 12 months after
ESWL [9]. It appears that persistence and growth of frag-
ments is common following ESWL [10-14]. In vitro [15-
17] and in vivo [9] studies suggest that citrate [9,15,16]
and phytate [17] can reduce residual post-ESWL calculi
fragment growth or agglomeration. Despite those find-
ings, however, there is a need for better understanding of
the factors that contribute to stone growth following
ESWL. Such knowledge will assist in designing methods
for preventing such growth.
The present study belongs to a series examining the
regrowth of residual post-ESWL calculi fragments in terms
of calculi type, urinary conditions and presence of crystal-
lization inhibitors. While a previous study examined
regrowth of calcium oxalate monohydrate (COM) resid-
ual post-ESWL calculi fragments [17], the present study
examined calcium oxalate dihydrate (COD) calculi frag-
ments.
Methods
The study used 48 spontaneously-passed post-ESWL frag-
ments of COD calculi collected on the day of the ESWL
procedure. Fragment selection proceeded according to the
general protocol applied by our laboratory in the study of
all renal stones. This methodology is based on a combina-
tion of optical stereomicroscopy, infrared spectrometry
and scanning electron microscopy (SEM) equipped with
an energy dispersive X-ray analyzer (EDS) [18]. All
selected fragments had a very similar morphology which
was representative of that observed in the majority of
spontaneously-passed post-ESWL COD calculi fragments.
Fragment sizes varied from 2 to 4 mm.
Fragments were not pre-treated, and were placed into four
hermetic flow chambers (3 cm diameter and 4 cm high),
with each chamber containing 12 fragments. These cham-
bers were then placed into a larger temperature-controlled
(37°C) chamber. Each chamber was used to test a differ-
ent incubation condition: pH = 5.5 and normocalciuria
([Ca total] = 3.75 mM), pH = 5.5 and hypercalciuria ([Ca
total] = 6.25 mM), pH = 6.5 and normocalciuria ([Ca
total] = 3.75 mM) and pH = 6.5 and hypercalciuria ([Ca
total] = 6.25 mM). The duration of all incubations was
192 h, except for those under pH = 6.5 hypercalciuric con-
ditions, which were for 48 h due to the high rate of frag-
ment mass increase. The methodology used was similar to
that previously described by Chow et al. [16,19]. Freshly
prepared synthetic urine was introduced into the flow
chambers using a multichannel peristaltic pump at a rate
of 750 mL/day through the bottom of the flasks. The cal-
culi fragments were placed on the porous flask bottom,
allowing the entire fragment surface to be exposed to the
artificial urine (see Figure 1). This system allows growth of
new crystals on the fragments. Fragment growth was eval-
uated by measuring the difference in weight between the
dried fragments before and after the experiment. The
weight of the fragments was measured using a precision
balance after the fragments had been kept in a desiccator
until their weight became constant, indicating complete
dryness. The mean growth rate of the 12 fragments under
each condition was calculated. The growth of the different
renal calculi fragments was standardized by calculating
the relative mass increase in order to avoid the effects that
different surface areas may have on growth rate measure-
ments.
Diagram of the experimental flow device used for COD cal- culi crystallization studies Figure 1
Diagram of the experimental flow device used for COD cal-
culi crystallization studies. 1. Temperature-controlled cham-
ber; 2. Flask containing post-ESWL calculi fragments; 3. 
Three-way T mixing chamber for A and B solutions; 4. A and 
B solutions for artificial urine; 5. Peristaltic pump.BMC Urology 2006, 6:16 http://www.biomedcentral.com/1471-2490/6/16
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The effects of the crystallization inhibitors phytate, pyro-
phosphate and citrate were evaluated. The concentrations
used corresponded to the physiological concentrations in
urine.
The experimental research has been performed with the
approval of the Bioethics Committee of the University of
Balearic Islands and the research was carried out in com-
pliance with the Helsinki Declaration.
Synthetic urine
Synthetic urine supersaturated with calcium oxalate was
prepared using a three-way T mixing chamber containing
equal volumes of solutions A and B (compositions shown
in Table 1). The pH of both solutions was adjusted either
to 5.5 or 6.5. Solutions were stored for a maximum of 1
week at 4°C. Chemicals of reagent-grade purity were dis-
solved in deionized and redistilled water. All solutions
were filtered through a 0.45 µm pore filter before use.
Effect of crystal inhibitors
Compounds reported to inhibit crystal formation were
added to the synthetic urine to the following final concen-
trations: 1.32–5.29 mM citrate as a sodium salt (supplied
by Probus), 0.15–4.55 µM phytate as a sodium salt (sup-
plied by Sigma), and 11.5–69.0 µM pyrophosphate as a
sodium salt (supplied by Merck).
Calcium-citrate complexation
Owing to the high concentration of citrate used, and con-
sidering its ability to complex with calcium ions, a cal-
cium supplement was used in experiments involving
citrate ions in order to achieve the same calcium oxalate
supersaturation value as occurs in the absence of citrate. It
must be noted that a decrease in supersaturation would
imply a decrease in the crystallization rate that could not
be assigned to inhibitory effects. The amount of calcium
ions added was potentiometrically calculated using a cal-
cium-selective electrode (Ingold) and a potentiometer
(Crison 2002). Calcium standards in the presence and
absence of citrate were prepared using synthetic urine as a
matrix. The activity of free calcium ions must be the same
in the presence and absence of citrate. Therefore, the cal-
cium concentration was increased by 0.15 mM per 0.53
mM increase in the citrate concentration. The levels of
phytate and pyrophosphate used were so low that the
decrease in free calcium concentration was negligible, as
determined potentiometrically. Consequently, it was not
necessary to add a calcium supplement to the solutions
containing phytate and pyrophosphate.
Results
Under all four incubation conditions, COM crystals were
found to form on COD calculi fragments (Figures 2, 3, 4,
5). New COD crystal formation represented the minority
(less than 50%) of crystal formation under pH = 5.5
hypercalciuric (Figure 3) and pH = 6.5 normocalciuric
COM and COD crystal formation on post-ESWL COD renal  calculi fragments following a 192 h incubation in hypercalciu- ric (6.25 mM) and normooxaluric (0.28 mM) synthetic urine  (pH = 5.5) Figure 3
COM and COD crystal formation on post-ESWL COD renal 
calculi fragments following a 192 h incubation in hypercalciu-
ric (6.25 mM) and normooxaluric (0.28 mM) synthetic urine 
(pH = 5.5).
Table 1: Composition of synthetic urine
Solution A (mM) Solution B (mM)
Na2SO4·10H2O 19.34 NaH2PO4·2H2O 15.45
MgSO4·7H2O 5.93 Na2HPO4·12H2O 15.64
NH4Cl 86.73 NaCl 223.08
KCl 162.60 Na2C2O4 0.57
Various volumes of a 1 M calcium solution (prepared by dissolving 
calcium carbonate with hydrochloric acid) were added to solution A 
to obtain final calcium concentrations ranging from 3.75–6.25 mM.
COM crystal formation on a post-ESWL COD renal calculus  fragment following a 192 h incubation in normocalciuric (3.75  mM) and normooxaluric (0.28 mM) synthetic urine (pH =  5.5) Figure 2
COM crystal formation on a post-ESWL COD renal calculus 
fragment following a 192 h incubation in normocalciuric (3.75 
mM) and normooxaluric (0.28 mM) synthetic urine (pH = 
5.5).BMC Urology 2006, 6:16 http://www.biomedcentral.com/1471-2490/6/16
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(Figure 4) conditions. In contrast, large amounts of COD
crystals formed under pH = 6.5 hypercalciuric conditions
(Fig 5a,c). Significant amounts of hydroxyapatite (HAP)
and brushite (BRU) crystals formed under pH = 6.5 hyper-
calciuria conditions (Figure 5a,b), but not under other
conditions.
The mean growth rates of COD calculi fragments under
the four incubation conditions are summarized in Table
2. While growth rates of 0.22–0.35 µg/mg·h were
observed under the majority of conditions, the rate was
approximately ten times greater (3.87 ± 0.43 µg/mg·h)
under pH = 6.5 hypercalciuria conditions.
The effects of three known crystallization inhibitors
(phytate, pyrophosphate and citrate) were investigated
(Figures 6 and 7). We found that addition of 2.27 µM
phytate to the pH = 5.5 hypercalciuria incubation, and the
addition of 4.55 µM phytate to the pH = 6.5 hypercalciu-
ria incubation completely inhibited the COD calculi frag-
ment mass increase. Addition of lower phytate
concentrations (less than 2.27 µM), mainly inhibited
COM crystal formation. The addition of 69.0 µM pyro-
phosphate to the pH = 6.5 hypercalciuria incubation
resulted in an 87% reduction of calculi fragment mass
increase. The addition of 5.29 mM citrate to the pH = 6.5
hypercalciuria incubation had no effect on the COD cal-
culi fragment mass increase.
Discussion
The present study found that in normocalciuric/nor-
mooxaluric urine at pH = 5.5, only new COM crystals
formed on COD calculi fragments. At the same pH, new
COD crystals only formed under hypercalciuric condi-
tions, in addition to COM crystals (Figure 3). Low phytate
concentrations (less than 2.27 µM), inhibited this COM
crystal formation. At pH = 6.5, COD crystals formed
under normocalciuric conditions (Figure 4), while under
hypercalciuria conditions the calcium phosphates HAP
and BRU also formed with the COD crystals. These find-
ings are consistent with several clinical observations
COM, COD and HAP crystal formation (arrows) on post- ESWL COD renal calculi fragments following a 192 h incuba- tion in normocalciuric (3.75 mM) and normooxaluric (0.28  mM) synthetic urine (pH = 6.5) Figure 4
COM, COD and HAP crystal formation (arrows) on post-
ESWL COD renal calculi fragments following a 192 h incuba-
tion in normocalciuric (3.75 mM) and normooxaluric (0.28 
mM) synthetic urine (pH = 6.5).
a) HAP and BRU crystal, b) COM and HAP crystal and c)  COD and HAP crystal formation on post-ESWL COD renal  calculi fragments following a 48 h incubation in hypercalciuric  (6.25 mM) and normooxaluric (0.28 mM) synthetic urine (pH  = 6.5) Figure 5
a) HAP and BRU crystal, b) COM and HAP crystal and c) 
COD and HAP crystal formation on post-ESWL COD renal 
calculi fragments following a 48 h incubation in hypercalciuric 
(6.25 mM) and normooxaluric (0.28 mM) synthetic urine (pH 
= 6.5).BMC Urology 2006, 6:16 http://www.biomedcentral.com/1471-2490/6/16
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showing that COM calculi are generally associated with a
lack of crystallization inhibitors and COD calculi with
hypercalciuria and high urinary pH values [3-6]. It is
important to emphasize that the growth rate of COD cal-
culi fragments was similar under all conditions except
under pH = 6.5 hypercalciuria, conditions under which
the growth rate was approximately ten times that observed
under other conditions (see Table 2). These findings sug-
gest that the presence of COD calculi fragments in the kid-
neys together with hypercalciuria and high urinary pH
values (around 6.5) are a high risk factor for stone devel-
opment. These data suggest that a COD calculus fragment
of only 5 mg could become a 45 mg fragment in just 3
months under these conditions.
Crystallization inhibitors can notably retard calculi frag-
ment development. The present study found that phytate
at concentrations found in normal human urine [20]
totally prevented COD calculi fragment growth. In addi-
tion, pyrophosphate also reduced the COD calculi frag-
ment mass increase. In contrast, citrate did not show any
significant crystallization inhibitory capacity under the
conditions investigated. This finding appears to be in dis-
agreement with previous reports showing that high citrate
concentrations reduced the growth rate of stones by more
than 50% [16]. However, this apparent discordance may
be because the stated growth rate reduction must be
assigned to citrate complexation with calcium, which
results in an important reduction in the relative calcium
oxalate supersaturation. Thus, it must be considered that
in the present study a calcium supplement was added to
obtain the same calcium oxalate supersaturation value
found in the absence of citrate. Interestingly, while citrate
did not inhibit calcium salt crystallization on COD crys-
tals in the present study, it was shown to inhibit calcium
salt crystallization on glycoproteins and organic matter
[21,22]. These observations again highlight the specificity
of crystallization inhibitors.
Conclusion
The growth rate of COD calculi fragments under pH = 6.5
hypercalciuria conditions was approximately ten times
that observed under other conditions. This observation
suggests COD calculi residual fragments in the kidneys
together with hypercalciuria and high urinary pH values
may represent an important risk factor for stone develop-
ment. In addition, the study found that specific crystalli-
zation inhibitors can effectively reduce calculi fragment
growth.
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Increase in the relative weight of post-ESWL COD renal cal- culi fragments incubated for 196 h in normooxaluric (0.28  mM) synthetic urine at pH = 5.5 in the absence or presence  of phytate Figure 6
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culi fragments incubated for 196 h in normooxaluric (0.28 
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